SAFETY AND EFFECTIVENESS OF SENSOR-CONTROLLED SCALP COOLING TO PREVENT ALOPECIA IN PRIMARY BREAST CANCER PATIENTS RECEIVING NEOADJUVANT OR ADJUVANT EPIRUBICIN, TAXANES, OR BOTH

CHRISTIAN M. KURBACHER1,2,3, SUSANNE HERZ1, GABRIELE KOLBERG1, NELE KETTELHOIT1,4, A. TABEA KURBACHER1,2, CLAUDIA SCHWEITZER1, JUTTA A. KURBACHER2, CHRISTIAN EICHLER1

1Gynecology I (Gynecologic Oncology), and 2Gynecology II (General Obstetrics and Gynecology), Gynecologic Center Bonn-Friedensplatz, Bonn, Germany; 3Faculty of Medicine, University of Cologne, Cologne, Germany; 4Faculty of Medicine, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany; Faculty of Medicine, Ruhr Universität Bochum, Bochum, Germany; Breast Center, Municipal Hospital Holweide, Cologne, Germany; 5Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V., (BNGO), Neuenhagen, Germany

Abstract

P6-11-14

INTRODUCTION

Sensor (Cold-activated Devices) in is a common side effect of systemic anti-cancer treatment, although not life-threatening and rarely irreversible. SC produces a temperature drop in a number of patients (20%) revealed particularly in summer. Recent literature reviews showed that the overall incidence of alopecia (all degree若您在研究过程中有任何问题，可以随时联系我，我的联系方式是...